Thursday, 1 Dec 2016

Noon – 1:00 PM: Registration & Working Lunch

1:00 – 2:40 PM: Session 1: Clinical Research in JMML
Moderator: Mignon Loh, UCSF Childrens Hospital

1:00 – 1:20 PM
● Alice Bertaina, Ospedale Bambino Gesu
“Identification of deregulated microRNAs in Juvenile Myelomonocytic Leukemia (JMML)”

1:20 – 1:40 PM
● Wenyu Yang, Diagnostic and Therapeutic Center of Children’s Blood Diseases
“The clinical characteristics and prognosis of Juvenile myelomonocytic leukemia in single institute from China”

1:40 – 2:00 PM
● Brigitte Strahm, University of Freiburg
“Second hematopoietic stem cell transplantation for patients with juvenile myelomonocytic leukemia”

2:00 – 2:20 PM
● Sarah Tasian, Children’s Hospital of Philadelphia
“CAR T Cell Immunotherapy for Myeloid Malignancies”

2:20 – 2:40 PM
● Charlotte Niemeyer, University of Freiburg
“Antileukemic activity of the DNA methyltransferase inhibitor azacitidine in a xenograft model of juvenile myelomonocytic leukemia”

2:40 – 3:00 PM Coffee Break

3:00 – 4:20 PM: Session 2: Risk Stratification for Patients Presenting with JMML
Moderators: Katherine Calvo and Elliot Stieglitz

3:00 – 3:20 PM
● Vollter Anastas, BS, Tufts University
“Whole Exome Sequencing Suggests Indolent Phenotype of RAS-Associated Autoimmune Leukoproliferative Disorder (RALD) is Characterized by Single Somatic Mutations in RAS Genes with Absence of Cooperating Mutations”

3:20 – 3:40 PM
● Hideki Muramatsu, Nagoya University
“Comprehensive genetic analysis in cases of juvenile myelomonocytic leukemia for prognostic estimation”

3:40 – 4:00 PM
● Mario Cazzola, University of Pavia
“Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia”

4:00 – 4:20 PM
● Elliot Stieglitz, UCSF Benioff Children’s Hospital
“Genome Wide DNA Methylation Profiling is Predictive of Outcome in Juvenile Myelomonocytic Leukemia”

4:20 – 5:20 PM: Session 3: Update on Clinical Trials
Moderator: Charlotte Niemeyer, MD, University of Freiburg

4:20 – 4:40 PM
● John Ceremsak, UCSF Benioff Children’s Hospital
“A Phase II Randomization of Conditioning Regimens in Juvenile Myelomonocytic Leukemia: Results from Children’s Oncology Group Trial ASCT1221”

4:40 – 5:00 PM
● Elliot Stieglitz, UCSF Benioff Children’s Hospital
“ADVL1521: A Phase 2 Study of the MEK inhibitor Trametinib in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia”

5:00 – 5:20 PM
● Tariq Arshad, KaloBios Pharmaceuticals
“Potential Use of KB003/Lenzilumab in JMML”

5:20 – 5:40 PM
● Charlotte Niemeyer, University of Freiburg
“Evaluation of azacitidine in pediatric MDS and JMML: What have we learned from AZA-JMML-001 so far?”

5:40 – 6:00 PM
● Steven Fruchtman, Onconova Therapeutics

6:30 – 8:00 PM: Dinner at Chianti (http://www.chiantirestaurantsd.com/) for meeting attendees and friends (self-pay)
Friday, 2 Dec 2016

8:00 – 9:00 AM: Working Breakfast

8:30 – 9:30 AM: Keynote Address:
Kevan Shokat, Ph.D.
Professor and Chair, Dept. of Cellular & Molecular Pharmacology, UCSF
Professor, Dept. of Chemistry, UC Berkeley
Investigator, Howard Hughes Medical Institute

9:30 – 10:15 AM: Session 4-1: Pre-Clinical Models and Genetics in JMML
Moderator: Rebecca Chan, Indiana University School of Medicine
9:30 – 9:45 AM  ● Lucy Liu, University of Arkansas
“An Age Specific Murine Model for Juvenile Myelomonocytic Leukemia (JMML)”
9:45 – 10:00 AM  ● Gen-Sheng Feng, UC San Diego
“Shp2 and Pten in leukemia and anemia”
10:00 – 10:15 AM  ● Lisa Deng, Indiana University
“Evaluation of Bruton’s Tyrosine Kinase and PI3K p110δ in Mutant Shp2-Induced Juvenile Myelomonocytic Leukemia”

10:15 – 10:30 AM: Coffee Break

10:30 – 11:30 AM: Session 4-2: Pre-Clinical Models and Genetics in JMML
Moderator: Rebecca Chan, Indiana University School of Medicine
10:30 – 10:45 AM  ● Lu Liu, University of Michigan
“N-RasG12D-mediated dysregulation of IRE1alpha-Xbp1s signaling promotes pre-leukemic hematopoietic stem cell expansion”
10:45 – 11:00 AM  ● Stefan Tarnawsky, Indiana University
“In Utero Expression Of Kras G12D Leads To A Rapidly Fatal Myeloid Disease In Mice”
11:00 – 11:15 AM  ● Elisa Dorantes, Boston Children’s Hospital
“RUNX1 is a Candidate Transcriptional Effector in Juvenile Myelomonocytic Leukemia”
11:15 – 11:30 AM  ● Feng-Chun Yang, University of Miami
“Role of ASXL1 in normal hematopoiesis and pathogenesis of myeloid malignancies”

11:30 – 12:30 PM: Lunch
Complete online Survey - https://www.surveymonkey.com/r/HHJ5YC6
Update on JMML Roadmap & Proposed topics for 2017 JMML meeting
Adjournment